HDE

H170002: LIPOSORBER LA-15 System

FDA Humanitarian Device Exemption · Kaneka Pharma America LLC

Key facts

HDE number H170002
Trade name LIPOSORBER LA-15 System
Generic name Apheresis for focal glomerulosclerosis in adult and pediatric patients
Applicant Kaneka Pharma America LLC
Owner/operator KANEKA CORP.
Product code PBN
Approval date Mar 20, 2018
Docket number 18M-1215
Notice date Apr 11, 2018
Establishment registration 3031408734
FEI number 3031408734

At a glance

  • 10–99 Supplements
  • Aug 26, 2026 Latest supplement decision
  • Yes Summary of safety and probable benefit on file
  • 1–9 UDI device identifiers (GUDID)
  • 1–9 MAUDE adverse event reports
  • None Recall events

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About HDE approvals

A Humanitarian Device Exemption (HDE) authorizes devices intended to benefit patients with rare diseases or conditions affecting small populations in the United States.

Source: U.S. Food and Drug Administration (FDA), Humanitarian Device Exemption (HDE) database · Source date:

Browse all HDE approvals